Angiopoietin-2 as a biomarker for metabolic syndrome and disease activity in rheumatoid arthritis patients

Egyptian Rheumatologist

Volumn 38, Issue 1, 2016, Pages 9-13

  Ghazaly, Abdel Hamed A Hares ^a   El Moez, Khalid M A ^a   El Shorbagy, Mohamed S ^b   El Nahrery, Eslam M ^c  

^a AL AZHAR UNIVERSITY   (Egypt)

^b AL AZHAR UNIVERSITY   (Egypt)

^c Suez University   (Egypt)

Author keywords

Angiopoietin 2; Disease activity score (DAS 28); Metabolic syndrome; Rheumatoid arthritis

Indexed keywords

ANGIOPOIETIN 2; BIOLOGICAL MARKER; GLUCOSE; TRIACYLGLYCEROL;

ADULT; AGE; ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE ACTIVITY; DISEASE ACTIVITY SCORE; DISEASE DURATION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; RHEUMATOID ARTHRITIS; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 84957430492     PISSN: 11101164     EISSN: 20902433     Source Type: Journal    
DOI: 10.1016/j.ejr.2015.03.001     Document Type: Article

References (39)

1. Stavropoulos-Kalinoglou A., Metsios G.S., Panoulas V.F., Douglas K.M., Nevill A.M., Jamurtas A.Z., et al. Associations of obesity with modifiable risk factors for the development of cardiovascular disease in patients with rheumatoid arthritis. Ann Rheum Dis 2009, 68(2):242-245.
2. Kassem E., Ghonimy R., Adel M., El-Sharnoby G. Non traditional risk factors of carotid atherosclerosis in rheumatoid arthritis. Egypt Rheumatol 2011, 33(3):113-119.
3. - in rheumatoid arthritis and correlation with disease activity. Egypt Rheumatol 2013, 35(4):185-192.
4. Gaber W., Azkalany G.S., Gheita T.A., Mohey A., Sabry R. Clinical significance of serum interleukin-6 and -174 G/C promoter polymorphism in rheumatoid arthritis patients. Egypt Rheumatol 2013, 35(2):107-113.
5. Gheita T.A., Azkalany G.S., Gaber W., Mohey A. Clinical significance of serum TNF-α and -308 G/A promoter polymorphism in rheumatoid arthritis. Egypt Rheumatol 2015, 37(2):49-54.
6. El-barbary A.M., Abdel Khalek M.A., Elsalawy A.M., Hazaa S.M. Assessment of lipid peroxidation and antioxidant status in rheumatoid arthritis and osteoarthritis patients. Egypt Rheumatol 2011, 33(4):179-185.
7. Hassan S.Z., Gheita T.A., Kenawy S.A., Fahim A.T., El-Sorougy I.M., Abdou M.S. Oxidative stress in systemic lupus erythematosus and rheumatoid arthritis patients: relationship to disease manifestations and activity. Int J Rheum Dis 2011, 14(4):325-331.
8. Gheita T.A., Kenawy S.A. Effectiveness of Nigella sativa oil in the management of rheumatoid arthritis patients: a placebo controlled study. Phytother Res 2012, 26(8):1246-1248.
9. Ghorbanihaghjo A., Hajialilo M., Shahidi M., Khabazi A., Kolahi S., Nakhjavani M.R.J., et al. Osteoprotegerin (OPG) and Matrix Gla protein (MGP) in rheumatoid arthritis patients: relation to disease activity. Egypt Rheumatol 2014, 36(3):111-116.
10. Abdalla M., Effat D., Sheta M., Hamed W.E. Serum leptin levels in rheumatoid arthritis and relationship with disease activity. Egypt Rheumatol 2014, 36(1):1-5.
11. Helal A.H., Shahine E.M., Hassan M.M., Hashad D.I., Abdel Moneim R. Fatigue in rheumatoid arthritis and its relation to interleukin-6 serum level. Egypt Rheumatol 2012, 34(4):153-157.
12. Ahmed S.F., Badr T., Hosny S.M., Aboul Hamayed H.F. Assessment of synovitis in early rheumatoid arthritis by CXCL13 serum levels and power Doppler ultrasonography: correlation with disease activity. Egypt Rheumatol 2013, 35(1):21-27.
13. +T regulatory cells in rheumatoid arthritis and the imbalance of the Treg/TH17 cytokine axis. Egypt Rheumatol 2015, 37(1):7-15.
14. Gheita T.A., Kenawy S.A., El Sisi R.W., Gheita H.A., Khalil H. Subclinical reduced G6PD activity in rheumatoid arthritis and Sjögren's syndrome patients: relation to clinical characteristics, disease activity and metabolic syndrome. Mod Rheumatol 2014, 24(4):612-617.
15. Costa C., Incio J., Soares R. Angiogenesis and chronic inflammation: cause or consequence?. Angiogenesis 2007, 10(3):149-166.
16. Haffner S.M., Valdez R.A., Hazuda H.P., Mitchell B.D., Morales P.A., Stern M.P. Prospective analysis of the insulin-resistance syndrome (syndrome X). Diabetes 1992, 41(6):715-722.
17. Grundy S.M., Brewer H.B., Cleeman J.I., Smith S.C., Lenfant C. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004, 109(3):433-438.
18. Lakka H.M., Laaksonen D.E., Lakka T.A., Niskanen L.K., Kumpusalo E., Tuomilehto J., et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002, 288(21):2709-2716.
19. Gheita T.A., El-Fishawy H.S., Nasrallah M.M., Hussein H. Insulin resistance and metabolic syndrome in primary gout: relation to punched-out erosions. Int J Rheum Dis 2012, 15(6):521-525.
20. Gheita T.A., Raafat H.A., Sayed S., El-Fishawy H., Nasrallah M.M., Abdel-Rasheed E. Metabolic syndrome and insulin resistance comorbidity in systemic lupus erythematosus. Effect on carotid intima-media thickness. Z Rheumatol 2013, 72(2):172-177.
21. Baraka E., El Dein M., Farouk H., El Moutaz Y. Hyperhomocysteinemia and metabolic syndrome are risk factors for sub-clinical atherosclerosis in women with systemic lupus erythematosus. Egypt Rheumatol 2015, 37(2):67-74.
22. El Sayed A.M., El Bakry S.A., Mobasher S.A., Abd El Rahman R., Abo-Shady R.A., Abaza N. Insulin resistance as a risk factor for subclinical atherosclerosis in rheumatoid arthritis. Egypt Rheumatol 2014, 36(1):7-13.
23. Alsalawy A.M., Fathi A.I., Kamel R.A., Ewis I. Correlation between serum osteoprotegerin and atherosclerotic vascular disorders in rheumatoid arthritis patients. Egypt Rheumatol 2012, 34(1):35-42.
24. Thurston G. Role of angiopoietins and Tie receptor tyrosine kinases in angiogenesis and lymphangiogenesis. Cell Tissue Res 2003, 314(1):61-68.
25. Roviezzo F., Tsigkos S., Kotanidou A., Bucci M., Brancaleone V., Cirino G., et al. Angiopoietin-2 causes inflammation in vivo by promoting vascular leakage. J Pharmacol Exp Ther 2005, 314(2):738-744.
26. Aletaha D., Neogi T., Silman A.J., Funovits J., Felson D.T., Bingham C.O., et al. 2010 Rheumatoid Arthritis Classification Criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010, 62(9):2569-2581.
27. National Cholesterol Education Program Expert Panel on Detection Evaluation, and Treatment of High Blood Cholesterol in Adults Third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001, 285:2486-2497.
28. Prevoo M.L., van't Hof M.A., Kuper H.H., van Leeuwen M.A., van de Putte L.B., van Riel P.L. Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995, 38:44-48.
29. Majithia V., Geraci S.A. Rheumatoid arthritis: diagnosis and management. Am J Med 2007, 120(11):936-939.
30. Maradit-Kremers H., Crowson C.S., Nicola P.J., Ballman K.V., Roger V.L., Jacobsen S.J., et al. Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum 2005, 52:402-411.
31. Libby P. Role of inflammation in atherosclerosis associated with rheumatoid arthritis. Am J Med 2008, 121(10 Suppl. 1):S21-S31.
32. Gale N.W., Thurston G., Hackett S.F., Renard R., Wang Q., McClain J., et al. Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by angiopoietin-1. Dev Cell 2002, 3(3):411-423.
33. Lieb W., Zachariah J.P., Xanthakis V., Safa R., Chen M.H., Sullivan L.M., et al. Clinical and genetic correlates of circulating angiopoietin-2 and soluble Tie-2 in the community. Circ Cardiovasc Genet 2010, 3(3):300-306.
34. Westra J., de Groot L., Plaxton S.L., Brouwer E., Posthumus M.D., Kallenberg C.G., et al. Angiopoietin-2 is highly correlated with inflammation and disease activity in recent-onset rheumatoid arthritis and could be predictive for cardiovascular disease. Rheumatology (Oxford) 2011, 50(4):665-673.
35. Soliman S.G., Korah T.E., Hammoda G.E., Mousa W. Significance of serum levels of angiopoietin-2 and its relationship to Doppler ultrasonographic findings in rheumatoid arthritis patients. Egypt Rheumatol 2014, 36(1):15-20.
36. Lim H.S., Blann A.D., Chong A.Y., Freestone B., Lip G.Y. Plasma vascular endothelial growth factor, angiopoietin-1, and angiopoietin-2 in diabetes: implications for cardiovascular risk and effects of multifactorial intervention. Diabetes Care 2004, 27(12):2918-2924.
37. Patel J.V., Lim H.S., Varughese G.I., Hughes E.A., Lip G.Y. Angiopoietin-2 levels as a biomarker of cardiovascular risk in patients with hypertension. Ann Med 2008, 40(3):215-222.
38. Anuradha S., Mohan V., Gokulakrishnan K., Dixit M. Angiopoietin-2 levels in glucose intolerance, hypertension, and metabolic syndrome in Asian Indians (Chennai Urban Rural Epidemiology Study-74). Metabolism 2010, 59(6):774-779.
39. Kennedy A., Ng C.T., Biniecka M., Saber T., Taylor C., O'Sullivan J., et al. Angiogenesis and blood vessel stability in inflammatory arthritis. Arthritis Rheum 2010, 62(3):711-721.